Condition: Intermediate and High-risk Non-muscle Invasive Bladder Cancer · Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.
This description comes directly from the study's public registry record.
Shouwei Zhao · 0518-82342973 · shouwei.zhao@hengrui.com
Always discuss trial participation with your own doctor first.
| Fudan University Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06108492